These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

166 related articles for article (PubMed ID: 22496445)

  • 1. Identification of intercellular cell adhesion molecule 1 (ICAM-1) as a hypoglycosylation marker in congenital disorders of glycosylation cells.
    He P; Ng BG; Losfeld ME; Zhu W; Freeze HH
    J Biol Chem; 2012 May; 287(22):18210-7. PubMed ID: 22496445
    [TBL] [Abstract][Full Text] [Related]  

  • 2. N-glycosylation deficiency reduces ICAM-1 induction and impairs inflammatory response.
    He P; Srikrishna G; Freeze HH
    Glycobiology; 2014 Apr; 24(4):392-8. PubMed ID: 24474243
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A mouse model of a human congenital disorder of glycosylation caused by loss of PMM2.
    Chan B; Clasquin M; Smolen GA; Histen G; Powe J; Chen Y; Lin Z; Lu C; Liu Y; Cang Y; Yan Z; Xia Y; Thompson R; Singleton C; Dorsch M; Silverman L; Su SM; Freeze HH; Jin S
    Hum Mol Genet; 2016 Jun; 25(11):2182-2193. PubMed ID: 27053713
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A Novel N-Tetrasaccharide in Patients with Congenital Disorders of Glycosylation, Including Asparagine-Linked Glycosylation Protein 1, Phosphomannomutase 2, and Mannose Phosphate Isomerase Deficiencies.
    Zhang W; James PM; Ng BG; Li X; Xia B; Rong J; Asif G; Raymond K; Jones MA; Hegde M; Ju T; Cummings RD; Clarkson K; Wood T; Boerkoel CF; Freeze HH; He M
    Clin Chem; 2016 Jan; 62(1):208-17. PubMed ID: 26430078
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Glycomic Characterization of Induced Pluripotent Stem Cells Derived from a Patient Suffering from Phosphomannomutase 2 Congenital Disorder of Glycosylation (PMM2-CDG).
    Thiesler CT; Cajic S; Hoffmann D; Thiel C; van Diepen L; Hennig R; Sgodda M; Weiβmann R; Reichl U; Steinemann D; Diekmann U; Huber NM; Oberbeck A; Cantz T; Kuss AW; Körner C; Schambach A; Rapp E; Buettner FF
    Mol Cell Proteomics; 2016 Apr; 15(4):1435-52. PubMed ID: 26785728
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Phosphomannose isomerase inhibitors improve N-glycosylation in selected phosphomannomutase-deficient fibroblasts.
    Sharma V; Ichikawa M; He P; Scott DA; Bravo Y; Dahl R; Ng BG; Cosford ND; Freeze HH
    J Biol Chem; 2011 Nov; 286(45):39431-8. PubMed ID: 21949237
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Natural Killer Cell Receptors and Cytotoxic Activity in Phosphomannomutase 2 Deficiency (PMM2-CDG).
    García-López R; de la Morena-Barrio ME; Alsina L; Pérez-Dueñas B; Jaeken J; Serrano M; Casado M; Hernández-Caselles T
    PLoS One; 2016; 11(7):e0158863. PubMed ID: 27415628
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Defective IGF-1 prohormone N-glycosylation and reduced IGF-1 receptor signaling activation in congenital disorders of glycosylation.
    Di Patria L; Annibalini G; Morrone A; Ferri L; Saltarelli R; Galluzzi L; Diotallevi A; Bocconcelli M; Donati MA; Barone R; Guerrini R; Jaeken J; Stocchi V; Barbieri E
    Cell Mol Life Sci; 2022 Feb; 79(3):150. PubMed ID: 35211808
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Synaptic roles for phosphomannomutase type 2 in a new Drosophila congenital disorder of glycosylation disease model.
    Parkinson WM; Dookwah M; Dear ML; Gatto CL; Aoki K; Tiemeyer M; Broadie K
    Dis Model Mech; 2016 May; 9(5):513-27. PubMed ID: 26940433
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Dissecting the transcriptional program of phosphomannomutase 2-deficient cells: Lymphoblastoide B cell lines as a valuable model for congenital disorders of glycosylation studies.
    Parrado A; Rubio G; Serrano M; De la Morena-Barrio ME; Ibáñez-Micó S; Ruiz-Lafuente N; Schwartz-Albiez R; Esteve-Solé A; Alsina L; Corral J; Hernández-Caselles T
    Glycobiology; 2022 Mar; 32(2):84-100. PubMed ID: 34420056
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Komrower Lecture. Congenital disorders of glycosylation (CDG): it's all in it!
    Jaeken J
    J Inherit Metab Dis; 2003; 26(2-3):99-118. PubMed ID: 12889654
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Increased biosynthesis of glycosphingolipids in congenital disorder of glycosylation Ia (CDG-Ia) fibroblasts.
    Sala G; Dupré T; Seta N; Codogno P; Ghidoni R
    Pediatr Res; 2002 Nov; 52(5):645-51. PubMed ID: 12409508
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Proteomic analysis of platelet N-glycoproteins in PMM2-CDG patients.
    de la Morena-Barrio ME; Di Michele M; Lozano ML; Rivera J; Pérez-Dueñas B; Altisent C; Sevivas T; Vicente V; Jaeken J; Freson K; Corral J
    Thromb Res; 2014 Mar; 133(3):412-7. PubMed ID: 24388574
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Dietary mannose supplementation in phosphomannomutase 2 deficiency (PMM2-CDG).
    Taday R; Grüneberg M; DuChesne I; Reunert J; Marquardt T
    Orphanet J Rare Dis; 2020 Sep; 15(1):258. PubMed ID: 32962735
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Deficiency of dolichol-phosphate-mannose synthase-1 causes congenital disorder of glycosylation type Ie.
    Imbach T; Schenk B; Schollen E; Burda P; Stutz A; Grunewald S; Bailie NM; King MD; Jaeken J; Matthijs G; Berger EG; Aebi M; Hennet T
    J Clin Invest; 2000 Jan; 105(2):233-9. PubMed ID: 10642602
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Clinical, biochemical and molecular phenotype of congenital disorders of glycosylation: long-term follow-up.
    Bogdańska A; Lipiński P; Szymańska-Rożek P; Jezela-Stanek A; Rokicki D; Socha P; Tylki-Szymańska A
    Orphanet J Rare Dis; 2021 Jan; 16(1):17. PubMed ID: 33407696
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Insufficient ER-stress response causes selective mouse cerebellar granule cell degeneration resembling that seen in congenital disorders of glycosylation.
    Sun L; Zhao Y; Zhou K; Freeze HH; Zhang YW; Xu H
    Mol Brain; 2013 Dec; 6():52. PubMed ID: 24305089
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A zebrafish model of congenital disorders of glycosylation with phosphomannose isomerase deficiency reveals an early opportunity for corrective mannose supplementation.
    Chu J; Mir A; Gao N; Rosa S; Monson C; Sharma V; Steet R; Freeze HH; Lehrman MA; Sadler KC
    Dis Model Mech; 2013 Jan; 6(1):95-105. PubMed ID: 22899857
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Serum transferrin carrying the xeno-tetrasaccharide NeuAc-Gal-GlcNAc2 is a biomarker of ALG1-CDG.
    Bengtson P; Ng BG; Jaeken J; Matthijs G; Freeze HH; Eklund EA
    J Inherit Metab Dis; 2016 Jan; 39(1):107-14. PubMed ID: 26335155
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Genomic organization of the human phosphomannose isomerase (MPI) gene and mutation analysis in patients with congenital disorders of glycosylation type Ib (CDG-Ib).
    Schollen E; Dorland L; de Koning TJ; Van Diggelen OP; Huijmans JG; Marquardt T; Babovic-Vuksanovic D; Patterson M; Imtiaz F; Winchester B; Adamowicz M; Pronicka E; Freeze H; Matthijs G
    Hum Mutat; 2000 Sep; 16(3):247-52. PubMed ID: 10980531
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.